Biallelic mutations in the CEBPA gene low CEBPA expression levels as prognostic markers in intermediate-risk AML

Hematology Journal

Volumn 4, Issue 1, 2003, Pages 31-40

  van Waalwijk van Doorn Khosrovani, Sahar Barjesteh ^a   Erpelinck, Claudia ^a   Meijer, Joost ^a   van Oosterhoud, Susanna ^a   van Putten, Wim L J ^a   Valk, Peter J M ^a   Beverloo, H Berna ^a   Tenen, Daniel G ^b   Löwenberg, Bob ^a   Delwel, Ruud ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

AML; CEBPA; Intermediate risk

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; DNA; FLT3 LIGAND; LEUCINE ZIPPER PROTEIN; MESSENGER RNA; TRANSCRIPTION FACTOR; COMPLEMENTARY DNA; RNA; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLELE; AMINO TERMINAL SEQUENCE; ANALYTIC METHOD; ARTICLE; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; DNA BINDING; FEMALE; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE INSERTION; GENE MUTATION; GRANULOCYTE; HAZARD ASSESSMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN DOMAIN; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SCREENING TEST; SEQUENCE ANALYSIS; STATISTICAL SIGNIFICANCE; ACUTE DISEASE; AMINO ACID SEQUENCE; BINDING SITE; BIOSYNTHESIS; CANCER STEM CELL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; KARYOTYPING; LIFE TABLE; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; MORTALITY; MYELOID LEUKEMIA; NUCLEOTIDE SEQUENCE; PROTEIN TERTIARY STRUCTURE; REMISSION; RISK; RISK FACTOR; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; SURVIVAL;

ACUTE DISEASE; ADOLESCENT; ADULT; ALLELES; AMINO ACID SEQUENCE; BINDING SITES; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DNA, COMPLEMENTARY; DNA, NEOPLASM; FEMALE; FRAMESHIFT MUTATION; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; KARYOTYPING; LEUCINE ZIPPERS; LEUKEMIA, MYELOID; LIFE TABLES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN STRUCTURE, TERTIARY; REMISSION INDUCTION; RISK; RISK FACTORS; RNA, MESSENGER; RNA, NEOPLASM; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; SURVIVAL ANALYSIS; TUMOR STEM CELLS;

EID: 0037591396     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200216     Document Type: Article

References (24)

1. Radomska HS, Huettner CS, Zhang P, Cheng T, Scadden DT, Tenen DG. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 1998; 18: 4301-4314.
2. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA 1997; 94: 569-574.
3. Vinson CR, Sigler PB, McKnight SL. Scissors-grip model for DNA recognition by a family of leucine zipper proteins. Science 1989; 246: 911-916.
4. Agre P, Johnson PF, McKnight SL. Cognate DNA binding specificity retained after leucine zipper exchange between GCN4 and C/EBP. Science 1989; 246: 922-926.
5. Landschulz WH, Johnson PF, Adashi EY, Graves BJ, McKnight SL. Isolation of a recombinant copy of the gene encoding C/EBP. Genes Dev 1988; 2: 786-800.
6. Williams SC, Cantwell CA, Johnson PF. A family of C/EBP-related proteins capable of forming covalently linked leucine zipper dimers in vitro. Genes Der 1991; 5: 1553-1587.
7. Thomassin H, Hamel D, Bernier D, Guertin M, Belanger L. Molecular cloning of two C/EBP-related proteins that bind to the promoter and the enhancer of the alpha 1-fetoprotein gene. Further analysis of C/EBP beta and C/EBP gamma. Nucleic Acids Res 1992; 20: 3091-3098.
8. Pei DQ, Shih CH. An 'attenuator domain' is sandwiched by two distinct transactivation domains in the transcription factor C/EBP. Mol Cell Biol 1991; 11: 1480-1487.
9. Nerlov C, Ziff EB. Three levels of functional interaction determine the activity of CCAAT/enhancer binding protein-alpha on the serum albumin promoter. Genes Dev 1994; 8: 350-362.
10. Friedman AD, McKnight SL. Identification of two polypeptide segments of CCAAT/enhancer-binding protein required for transcriptional activation of the serum albumin gene. Genes Der 1990; 4: 1416-1426.
11. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001; 27: 263-270.
12. Gombart AF, Hofmann WK, Kawano S, Takeuchi S, Krug U, Kwok SH et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 2002; 99: 1332-1340.
13. Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, De Botton S et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002; 100: 2717-2723.
14. Ossipow V, Descombes P, Schibler U. CCAAT/enhancer-binding protein mRNA is translated into multiple proteins with different transcription activation potentials. Proc Natl Acad Sci USA 1993; 90: 8219-8223.
15. Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med 2001; 7: 444-451.
16. Boyum A. Separation of leukocytes from blood and bone marrow. Introduction. Scand J Clin Lab Invest Suppl 1968; 97: 7.
17. Delwel R, Touw I, Bot F, Lowenberg B. Fucose binding lectin for characterizing acute myeloid leukemia progenitor cells. Blood 1986; 68: 41-45.
18. Rombouts WJ, Lowenberg B, van Putten WE, Ploemacher RE. Improved prognostic significance of cytokine-induced proliferation in vitro in patients with de novo acute myeloid leukemia of intermediate risk: impact of internal tandem duplications in the Flt3 gene. Leukemia 2001; 15: 1046-1053.
19. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620-625.
20. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911-1918.
21. Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001; 97: 89-94.
22. Kondo M, Horibe K, Takahashi Y, Matsumoto K, Fukuda M, Inaba J et al. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med Pediatr Oncol 1999; 33: 525-529.
23. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-1759.
24. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WLJ, Valk PJM, van der Poel - van de Luytgaarde S, Hack R et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.. Blood 2003; 101: 837.